Myriad Genetics takes cancer awareness to the Midwest

Share this article:
Myriad Genetics takes cancer awareness to the Midwest
Myriad Genetics takes cancer awareness to the Midwest
In an extension of a long-running hereditary breast and cancer awareness campaign, Myriad Genetics launched consumer advertising materials in five Midwest states on Monday.

The campaign targets women ages 25 to 54 with a family or personal history of breast or ovarian cancer, and physicians who care for these women on an ongoing basis, according to a spokesperson at Ogilvy, the campaign's public relations firm. Professional outreach includes educating physicians on how to identify appropriate patients. Myriad's other agency partners on the campaign include Lehman Millet and Blitz Media.

Television spots running on network channels through spring of 2010 will include branded messages for the BRACAnalysis test, a blood test that can determine a woman's level of risk for breast or ovarian cancer, although200 the overall campaign is an unbranded awareness initiative, the spokesperson said. Ads drive traffic to www.bracnow.com, and by phone to 1-866-BRACNOW. Outreach to physicians began six months ago in the form of meetings, letters and emails, the spokesperson said.

The Midwest campaign is an extension of an initiative that began in the Northeast in 2007/2008 and was rolled out in Florida and Texas last year, the spokesperson said. The current campaign is running in Illinois, Indiana, Kentucky, Missouri and Ohio.   

Share this article:

Email Newsletters

More in News

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.